Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer

Cold Spring Harbor Protocols

Volumn 4, Issue 8, 2009, Pages

  Verhoeyen, Els ^a   Cosset, François Loïc ^a  

^a Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73349116540     PISSN: None     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top59     Document Type: Review

References (69)

1. Ager S, Nilson BHK, Morling FJ, Peng KW, Cosset F-L, Russell SJ. 1996. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther 7: 2157-2164.
2. Barnett AL, Davey RA, Cunningham JM. 2001. Modular. organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc Natl Acad Sci 98: 4113-4118.
3. Battini JL, Danos O, Heard JM. 1998. Definition of a 14-amino-acid pepticle essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor. J Virol 72: 428-435.
4. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. 1999. Targeting retroviral vectors to CD34-expressing cells: Binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 10: 545-557.
5. Buchholz CJ, Peng K-W, Morling FJ, Zhang J, Cosset F-L, Russell SJ. 1998. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 16: 951-954.
6. Chadwick MP, Moding FJ, Cosset F-L, Russell SJ. 1999. Modification of retroviral tropism by display of IGF-I. J Mol Biol 285: 485-494.
7. Christocloulopoulos I, Cannon P. 2001. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol 75: 4129-4138.
8. Chu TH, Martinez I, Sheay WC, Dornburg R. 1994. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther 1: 292-299.
9. Cosset F-L, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. 1995. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69: 6314-6322.
10. Dardalhon V, Herpers B, Noraz N, Pflumio F, Guetard D, Leveau C, Dubart-Kupperschmitt A, Charneau P, Taylor N. 2001. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther 8: 190-198.
11. DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, Dubensky TW. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2: 218-222.
12. Duisit G, Conrath H, Saleun S, Folliot S, Provost N, Cosset F-L, Sandrin V, Moullier P, Rolling F. 2002. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther 6: 446-454.
13. Fass D, Davey RA, Hamson CA, Kim PS, Cunningham JM, Berger JM. 1997. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science 277: 1662-1666.
14. Fielding AK, Maurice M, Morling FJ, Cosset F-L, Russell SJ. 1998. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 91: 1802-1809.
15. Fielding AK, Chapel-Fernandes S, Chadwick M, Bullough F, Cosset F-L, Russell S. 2000. A hyperfusogenic Gibbon ape leukemia virus envelope glycoprotein: Targeting of a-cytotoxic gene by ligand display. Hum Gene Ther 11: 817-826.
16. + marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood 98: 2065-2070.
17. Gollan TJ, Green MR. 2002. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope. J Virol 76: 3558-3563.
18. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, Vanin EF, Nienhuis AW. 2002. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5: 242-251.
19. Hard I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. 2005. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther 12: 918-926.
20. Kasahara N, Dozy AM, Kan YW. 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376.
21. Kayman SC, Park H, Saxon M, Pinter A. 1999. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol 73: 1802-1808.
22. Kelly P, Vandergriff J, Nathwani A, Nienhuis A, Vanin E. 2000. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 96: 1206-1214.
23. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. 2001. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 19: 225-230.
24. Kootstra NA, Zwart BM, Schuitemaker H. 2000. Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G1 phase of the cell cycle. J Virol 74: 1712-1717.
25. Lavillette D, Boson B, Russell S, Cosset F-L. 2001. Membrane fusion by murine leukemia viruses is activated in cis or in trans by interactions of the receptor- binding domain with a conserved disulfide loop at the carboxy-terminus of the surface glycoproteins. J Virol 75: 3685-3695.
26. Lindemann D, Bock M, Schweizer M, Rethwilm A. 1997. Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J Virol 71: 4815-4820.
27. Linder M, Linder D, Hahnen J, Schott HH, Stirm S. 1992. Localization of the intrachain disulfide bonds of the envelope glycoprotein 71 from Friend murine leukemia virus. Eur J Biochem 203: 65-73.
28. Linder M, Wenzel V, Linder D, Stirm S. 1994. Structural elements in glycoprotein 70 from polytropic Friend mink cell focus-inducing virus and glycoprotein 71 from ecotropic Friend murine leukemia virus, as defined by disulfide-bonding pattern and limited proteolysis. J Virol 68: 5133-5141.
29. Lorimer IA, Lavictoire SJ. 2000. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J Immunol Methods 237: 147-157.
30. + cells. J Virol 71: 3341-3345.
31. - primitive cells capable of reconstituting long-term cultures in vitro and in nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 9.
32. Martin F, Neil S, Kupsch J, Maurice M, Cosset F-L, Collins M, 1999. Retrovirus targeting by tropism restriction to melanoma cells. J Virol 73: 6923-6929.
33. Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK. 2002. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 5: 269-274.
34. Matano T, Odawara T, Iwamoto A, Yoshikura H. 1995. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 76: 3165-3169.
35. Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MKL, Russell SJ, Cosset F-L. 1999. Efficient gene delivery to quiescent IL2-dependent cells by murine leukemia virus-derived vectors harboring IL2 chimeric envelopes glycoproteins. Blood 94: 401-410.
36. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset F-L. 2002. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99: 2342-2350.
37. Morling FJ, Peng KW, Cosset FL, Russell SJ. 1997. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 234: 51-61.
38. Movassagh M, Desmyter C, Baillou C, Chapel-Fernandes S, Guigon M, Klatzmann D, Lemoine FM. 1998. High-level gene transfer to cord-blood progenitors using gibbon ape leukemia virus pseudotyped retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 9: 225-234.
39. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
40. Nère D, Duisit G, Mangeot P-E, Moullier P, Darlix J-L, Cosset F-L. 2002. Lentiviral vectors derived from simian immunodeficiency virus (SIV). Curr Top Microbiol Immunol 261: 53-74.
41. Neil S, Martin F, Ikeda Y, Collins M. 2001. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 75: 5448-5456.
42. Nguyen T, Pages J-C, Farge D, Briand P, Weber A. 1998. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. Hum Gene Ther 9: 2469-2479.
43. Nilson BHK, Morling FJ, Cosset F-L, Russell SJ. 1996. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 3: 280-286.
44. Peng KW, Morling FJ, Cosset F-L, Murphy G, Russell SJ. 1997. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 8: 729-738.
45. Peng KW, Morling FJ, Cosset F-L, Russell SJ. 1998. A retroviral gene delivery system activatable by plasmin. Tumor Targeting 3: 112-120.
46. Peng K-W, Vile RG. Cosset F-L, Russell SJ. 1999. Selective transduction of protease-rich tumors by matrix- metalloproteinase-targeted retroviral vectors. Gene Ther 6: 1552-1557.
47. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset F-L, Russell SJ. 2001. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 8: 1456-1463.[Medline]
48. Porter CD, Collins MKL, Tailor CS, Parker MH, Cosset F-L, Weiss RA, Takeuchi Y. 1996. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther 7: 913-919.
49. Rodrigues P, Heard JM. 1999. Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2. J Virol 73: 3789-3799.
50. Russell SJ, Hawkins RE, Winter G. 1993. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21: 1081-1085.
51. + cells derived from human and non-human primates. Blood 100: 823-832.
52. Schneider RM, Medvedovska Y, Hard I, Voelker B, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. 2003. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther 10: 1370-1380.
53. Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, Kurth R, Groner B, Cichutek K. 1997. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci 94: 8640-8645.
54. Seganti L, SuperLi F, Girmenia C, Melucci L, Orsi N. 1986. Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells. Microbiologica 9: 259-267.
55. + T cells enables preservation of a naive repertoire. J Immunol 161: 5909-5917.
56. Stitz J, Buchholz C, Engelstadter M, Uckert W, Bloemer U, Schmitt I, Cichutek K. 2000. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 273: 16-20.
57. Sutton RE, Reitsma MJ, Uchida N, Brown PO. 1999. Transduction of human progenitor hernatopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 73: 3649-3660.
58. Szécsi J, Drury R, Josserand V, Grange M-P, Boson B, Hard I, Schneider R, Buchholz C, Coll J-L, Russell SJ, et al. 2006. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 14: 735-744.
59. Takeuchi Y, Simpson G, Vile R, Weiss R, Collins M. 1992. Retroviral pseuclotypes produced by rescue of moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology 186: 792-794.
60. Uckert W, Willimsky G, Pedersen FS, Blankenstein T, Pedersen L. 1998. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum Gene Ther 9: 2619-2627.
61. Valsesia-Wittmann S, Drynda A, Deleage G, Aumailley M, Heard I-M, Danos O, Verdier G, Cosset F-L. 1994. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 68: 4609-4619.
62. Valsesia-Wittmann S, Morling FJ, Nilson BHK, Takeuchi Y, Russell SJ, Cosset F-L. 1996. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol 70: 2059-2064.
63. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset F-L. 1997. Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J 16: 1214-1223.
64. Verhoeyen E, Cosset F-L. 2009. Hematopoietic stem cell targeting with surface-engineered lentiviral vectors. Cold Spring Harb Protoc (this issue). doi: 10.1101/pdb.prot5276.
65. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, Trono D, Taylor N, Cosset F-L. 2003. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T-lymphocytes. Blood 101: 2167-2174.
66. Verhoeyen E, Wiznerowicz M, Olivier D, Izac B, Trono D, Dubart-Kupperschmitt A, Cosset FL. 2005. Novel lentiviral vectors displaying "early acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106: 3386-3395.
67. + T-cell pool. Immunology 98: 400-405.
68. Wu BW, Cannon PM, Gordon EM, Hall FL, Anderson WF. 1998. Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol 72: 5383-5391.
69. Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. 2000. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology 269: 7-17.